Objectives: In the absence of other therapeutic options, tigecycline is used to treat bloodstream infections and pneumonia caused by carbapenemase-producing Klebsiella pneumoniae (CP-Kp). In this study, the standard and high tigecycline dosing regimens were simulated and tested against different inocula of CP-Kp isolates in an in vitro pharmacokinetic (PK)/pharmacodynamic (PD) model.
Introduction
The emergence of MDR Klebsiella pneumoniae isolates that cause serious nosocomial infections with high mortality rates is alarming. 1 The MDR profile of these pathogens limits the therapeutic options for managing these infections. However, these pathogens often retain in vitro susceptibility to tigecycline. 2 Tigecycline is a glycylcycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit; it demonstrates a broadspectrum bacteriostatic activity against a variety of Gramnegative, Gram-positive, anaerobic and atypical MDR bacteria, including isolates with drug-specific efflux pumps, ribosomal protection and carbapenemases. 3, 4 Tigecycline is indicated for the treatment of complicated skin and skin structure infections, complicated intra-abdominal infections and community-acquired bacterial pneumonia as a 100 mg loading dose followed by 50 mg twice every 24 h. 5 In the absence of other therapeutic options tigecycline is often used off-label for difficult-to-treat infections caused by MDR bacteria, such as carbapenem-resistant bacterial bloodstream infections and hospital-acquired pneumonia. 5 However, there are few available clinical or experimental data supporting the utility of tigecycline as monotherapy for these infections, with some reports associating tigecycline monotherapy with increased mortality for bloodstream infections. 6 The fact that higher doses of tigecycline were found to be more effective than the standard dose of 50 mg every 12 h for the treatment of ventilator-associated pneumonia indicates that there is a place for dose optimization. evaluated the efficacy of the standard and high tigecycline dosing regimens for infections by isolates with increasing tigecycline MICs and bacterial loads.
Materials and methods

Isolates, drugs and medium
Four clinical isolates of K. pneumoniae were used: three isolates (Tzan59, 6/ 100 and Sec4) were susceptible to tigecycline with EUCAST MICs of 0.125, 0.25 and 1 mg/L, respectively, and one isolate (Sec2) was intermediately susceptible to tigecycline with an MIC of 2 mg/L. The isolates 6/100, Sec4 and Sec2 are VIM carbapenemase-producing K. pneumoniae clinical isolates. In order to verify the results found for VIM carbapenemaseproducing K. pneumoniae we also used two KPC carbapenemaseproducing K. pneumoniae isolates 1433 and 1509 with tigecycline MICs of 2 and 0.5 mg/L, respectively. The isolates (kindly provided by Dr V. Miriagou, Laboratory of Bacteriology, Hellenic Pasteur Institute) were stored at 2708C and revived after subculturing on MacConkey agar plates at 378C for 18-24 h. Bacterial suspensions were prepared in normal saline from cultures in Mueller -Hinton agar plates and adjusted to a turbidity equivalent to that of a 0.5 McFarland standard with a densitometer (bioMé rieux, France) in order to obtain final concentrations of 10 7 , 10 5 and 10 3 cfu/mL as starting inocula, verified by quantitative cultures. Clinical formulations of tigecycline (Tigecycline 5 g, Pfizer, Greece) and cation-adjusted Mueller-Hinton broth (CAMHB) were used. All isolates were tested twice. Escherichia coli ATCC 25922 (tigecycline MIC ¼ 0.06 mg/L) was used as the quality control strain for in vitro susceptibility testing and in the in vitro PK/PD model.
In vitro PK/PD model
A previously developed closed diffusion/dialysis in vitro PK model 8 recently adapted to simulate human PK of antibacterial drugs was used. 9 The model consists of two compartments, the internal and the external. The external compartment consists of a conical flask containing 700 mL CAMHB placed on a heated magnetic stirrer adjusted at 378C. The internal compartment consists of a tube of semipermeable cellulose membrane (Float-A-Lyzer w , Spectrum Labs, Breda, The Netherlands) allowing bidirectional diffusion of the drug and of the medium, but preventing the escape of bacteria. Each tube contains 10 mL CAMHB and the bacterial isolate.
In order to simulate the biphasic decline of tigecycline concentrations after 1 h infusion, tigecycline was added simultaneously in both compartments. After 1 h of incubation, the internal compartment was transferred to a new external compartment with drug-free CAMHB, simulating the first elimination phase with a short half-life (,2 h). After an additional 1 h of incubation, a second transfer took place to a new external compartment with CAMHB containing the trough levels of tigecycline, simulating the second elimination phase with a long half-life (.24 h). 10 This procedure was repeated every 24 h for 48 h, simulating the daily tigecycline human PK.
In vitro PK
The standard dosing regimen of 50 mg tigecycline every 12 h as a 1 h infusion was simulated in the in vitro model. This dosing regimen resulted in total peak/trough concentrations of 0.62/0.13 mg/L, 11 whereas lung parenchymal tissue concentrations were reported to be 10 times higher than total serum concentrations. 12 In addition, taking into account the 80% protein binding 10 and the epithelial lining fluid (ELF)/total serum concentration ratio of 1.32 previously found in healthy volunteers, 13 the ELF/free serum concentration is 6.6, which may increase 2-to 3-fold during infection as found in an animal model. 14 Thus, free peak/trough serum and lung concentrations of 0.125/0.015 and 1.25/0.15 mg/L were simulated in the model, respectively. Drug levels were determined at regular intervals by an agar diffusion microbiological assay using as indicator a susceptible Bacillus cereus strain in Bacto TM Agar (BD). 15 The method detects concentrations from 0.125 to 64 mg/L with good reproducibility (coefficient of variation ,25%). The area under the concentration -time curve from 0 to 24 h (AUC 0 -24 ) was calculated for each dosing regimen, isolate and experiment.
In vitro PD
The bacterial load in the internal compartment was evaluated at regular intervals by 20 mL sampling followed by 1/10 serial dilutions in saline and quantitative cultures on Mueller -Hinton agar plates and incubation for 24 h at 378C. Time-kill curves were constructed by plotting log 10 cfu/mL over time for each isolate and dosing regimen.
In vitro PK/PD analysis
For each dosing regimen, isolate and experiment, the PK/PD index AUC 0 -24 /MIC was calculated using the MIC determined on the same day of the experiment. The relationship between the PK/PD index and 48 h log 10 cfu/mL reduction at each dosing regimen and isolate compared with drug-free control was analysed for each of the three inocula by nonlinear regression using the E max model described by the equation:
, where E is the log 10 cfu/mL reduction compared with drug-free control (dependent variable), E max is the maximum reduction in log 10 cfu/mL (i.e. 8 log 10 cfu/mL) observed at high drug exposures, E min is the minimum reduction in log 10 cfu/mL (i.e. 0 log 10 cfu/mL) observed in the drug-free control, fEI is the PK/PD index fAUC 0 -24 /MIC (independent variable), fEI 50 is the EI corresponding to 50% of E max (i.e. 4 log 10 cfu/mL reduction) and m is the slope of the concentration-effect curve (Hill coefficient) (GraphPad Prism 4.03). In order to describe the full PK/PD relationship, different dosing regimens with a C max of up to 4 mg/L were tested. A similar analysis was performed using the 24 h log 10 cfu/mL. The fEI 50 and tEI 50 (calculated as described below) were then plotted against each inoculum after log 10 transformation and analysed with linear regression analysis.
Monte Carlo simulation
In order to bridge the in vitro data with human PKs, Monte Carlo simulation analysis was performed using the log mean and SD of tigecycline exposures and the normal random number generator function of Excel (MS Office 2007) for 10 000 patients infected with K. pneumoniae isolates with tigecycline MICs ranging from 0.03 to 4 mg/L treated with 50 and 100 mg of tigecycline every 12 h as a 1 h infusion. These dosages resulted in steady-state mean+SD total C max and AUC 0 -12 of 0.62+0.09 mg/L and 3.07+0.38 mg . h/L for the 50 mg and 1.17+0.18 mg/L and 4.98+0.93 mg . h/L for the 100 mg dosage, respectively. 10 Thus, the total AUC 0 -24 was calculated to be 6.14+0.76 and 9.96+1.86 mg . h/L, respectively. The percentage of patients attaining the PK/PD target was calculated at each MIC for serum and lung drug exposures and a PK/PD susceptibility breakpoint was determined.
Since the in vitro concentrations are free drug concentrations as opposed to in vivo concentrations, which are total concentrations, the in vitro PK/PD target based on total drug exposure was calculated taking into account the concentration-dependent protein binding of tigecycline, which ranges from 80% at higher concentrations (.1 mg/L) to 0% at very low concentrations (,0.05 mg/L) and follows the equation y ¼ 9.0896 +15.339/x 2 0.999/x 2 +0.0232/x 3 , where y is the percentage of free fraction and x is the total plasma concentration. 16 Based on this equation, each in vitro free drug concentration was converted into the corresponding total drug concentration and the total AUC 0 -24 /MIC associated with 50% of maximal efficacy was calculated (tEI 50 ). This PK/PD target, together with the upper and lower 95% CI limit obtained with the linear regression analysis of log tEI 50 versus log 10 cfu/mL for bacterial 173 Bacterial load and pharmacodynamics of tigecycline JAC burden from 10 7 to 10 0 cfu/mL, was used to calculate the PTA for isolates with MICs ranging from 0.03 to 4 mg/L. In addition, the serum and lung tAUC 0 -24 required to attain the PK/PD target for each MIC and bacterial load was plotted.
Results
In vitro PK Figure 1 shows the in vitro PK of the 50 mg every 12 h dosing regimen simulating free serum and lung concentrations. Values were close to the target concentrations of the human PK of tigecycline in the in vitro model with an average (range) fC max of 0.125 (0.10 -0.15) and 1.25 (1 -1.5) mg/L, respectively, for all isolates. A decrease up to 50% of peak concentrations of tigecycline was observed within 1 h after the end of simulated infusion, following a biphasic decline with a short alpha half-life and a longer beta half-life. The mean+SD fAUC 0 -24 among all isolates, inocula, experiments and dosing intervals was 12.4+1.24 mg . h/L for lung concentrations and 1.24+0.12 mg . h/L for serum concentrations. Because of the sensitivity limit of the bioassay, serum concentrations were extrapolated from the lung concentrations since the former were 1/10 dilutions of the later. The median (range) coefficient of variation was 18% (10% -33%) among the four dosing intervals and 20% (15% -26%) among the isolates and inocula. The predicted mean+SD tAUC 0 -24 was 109+9.73 mg . h/L for lung concentrations and 2.79+0.49 mg . h/L for serum concentrations. Figure 2 show the time -kill curves for each dosing regimen, isolate and inoculum. Using a starting inoculum of 10 7 cfu/mL, a small (1 -3 log 10 cfu/mL) decline in the bacterial counts was observed followed by regrowth to drug-free control levels for all isolates and in both serum and lung concentrations. Using a lower starting inoculum, a bacteriostatic and killing effect was observed in lung concentrations against the most susceptible isolate with 10 5 and 10 3 cfu/mL, respectively. A bacteriostatic effect was also found with serum concentrations with both lower inocula against the most susceptible isolate, but only at 24 h, followed by regrowth at 48 h. The same effect was found for KPC carbapenemaseproducing K. pneumoniae isolates (Figure 3) . The MICs for the isolates at the end of 48 h experiments simulating serum and lung concentrations did not increase compared with the initial MICs. A 2-to 4-fold increase was observed when higher drug exposures were simulated in the in vitro model targeting C max of 2.8 mg/L. When the E. coli ATCC 25922 strain was used at 10 7 cfu/mL in the in vitro model simulating tigecycline lung concentrations, complete eradication was found after 24 h with no regrowth observed at 48 h (data not shown).
In vitro PD
In vitro PK/PD
The PK/PD relationship of tigecycline is shown in Figure 4 (a), and followed a sigmoid curve (R 2 .0.80). The size of the starting inoculum had a significant impact on the fEI 50 concentration of tigecycline, which decreased from 79 (23 -245) with a starting inoculum of 10 7 cfu/mL to 28 (19 -41) with a starting inoculum of 10 5 cfu/mL and 16 (12 -28) with a starting inoculum of 10 3 cfu/mL using 48 h log 10 cfu/mL. When free drug levels were transformed to total drug levels, the estimated median (range) percentage protein binding was 88% (89%-26%) for concentrations .0.1 mg/L as previously found. 16 The in vitro tEI 50 was 150 for the 10 3 cfu/mL inoculum, 236 for the 10 5 cfu/mL inoculum and 590 for the 10 7 cfu/mL inoculum. When the 24 h log 10 cfu/mL was used, a lower EI 50 was found compared with 48 h PK/PD analysis only for the 10 3 cfu/mL (8.3 for free drug levels and 49 for total drug levels) (data not shown). The relationship between the 48 log 10 cfu/mL of initial inoculum and the log 10 
Monte Carlo simulation
The mean+SD AUC 0 -24 of the simulated patient population was 6.14+0.76 mg . h/L for the 50 mg dose and 9.98+1.86 mg . h/L for the 100 mg dose. High (100%) PTA were found for serum drug exposures only at low inocula of 10 3 and 10 1 cfu/mL for isolates with MICs of ≤0.03 and ≤0.06 mg/L, respectively with both the 50 and 100 mg doses, whereas intermediate (60% -80%) PTA were found for isolates with 10 3 cfu/mL and MICs of 0.06 and 0.125 mg/L only for the 100 mg dose, respectively. The PTA for lung drug exposures after dosages of 50 and 100 mg every 12 h Bacterial load and pharmacodynamics of tigecycline JAC were .94% for isolates with MICs of ≤0.06 and ≤0.125 mg/L for an initial inoculum of 10 7 cfu/mL, MICs of ≤0.125 and ≤0.25 mg/L for an initial inoculum of 10 5 cfu/mL and MICs of ≤0.25 and ≤0.5 mg/L for an initial inoculum of 10 3 cfu/mL, respectively ( Figure 5 ). The optimal serum and lung tigecycline exposure required for each MIC and bacterial burden is shown in Figure 6 . The standard tigecycline dose of 50 mg can provide sufficient serum exposure for bacteraemias with ≤10 1 cfu/mL by isolates with MICs of ≤0.06 mg/L, whereas the higher dose of 100 mg would be required for isolates with MICs of 0.125 and 0.25 mg/ L, increasing the risk of increased toxicity, which is associated with tAUC 0 -24 .6.87. 17 For pneumonia with 10 3 -10 5 cfu/mL, the standard dose can provide sufficient lung exposure for isolates with MICs of ≤0.25 mg/L, whereas for isolates with MICs of 0.5 mg/L, the higher dose will be required.
Discussion
In vitro PK/PD analysis of tigecycline and K. pneumoniae showed inoculum-dependent PD with an fAUC 0 -24 /MIC (tAUC 0 -24 /MIC) associated with a half-maximal activity of 16 (150) with 10 3 cfu/mL, 28 (239) with 10 5 cfu/mL and 79 (590) with 10 7 cfu/mL. These targets were attained with serum tigecycline exposures only for isolates with MICs ≤0.06 mg/L and 10 1 cfu/mL and ≤0.125 mg/L and 10 0 cfu/mL, whereas, for lung drug exposures, the PD targets were attained for isolates with MICs of ≤0.06 mg/L and 10 7 cfu/mL, ≤0.12 mg/L and 10 5 cfu/mL and ≤0.25 mg/L and 10 3 cfu/mL with the standard dose of 50 mg. With the higher dose of 100 mg, the target was attained for isolates one dilution higher.
Tigecycline serum concentrations in the in vitro model were not effective even with the lowest inoculum; a bacteriostatic activity was found at 24 h followed by regrowth only for isolates with low MICs (≤0.25 mg/L). Given the absence of MIC increase after exposure to serum and lung concentrations of tigecycline, emergence of resistance may be not an issue at those concentrations, but rather at higher super-physiological free concentrations (.2 mg/L) as we found in the present study. This is in line with the low prevalence of tigecycline resistance among clinical isolates. 18 Interestingly, when E. coli ATCC 25922 at 10 7 cfu/mL with a tigecycline MIC of 0.06 mg/L was tested in the in vitro model, complete eradication was found at an fAUC 0-24 /MIC ratio .100. Such ratios can be obtained with serum concentrations only for K. pneumoniae isolates with MICs of ≤0.06 mg/L, which represents only 1% of all isolates (http://mic.eucast.org/Eucast2/). This is in line with the higher mortality observed in patients with bloodstream bacterial infections treated with tigecycline alone compared with other drugs. 6 Of note, clinical cure has been observed in K. pneumoniae bloodstream infections although in patients who had either community-acquired infections and low APACHE scores (mean 7.3), 19 or had previously received other antibiotics. 20 Tigecycline could be effective in treatment of bacteraemia with low (,10 cfu/mL) bacterial loads typically seen in adults, which often have ,1 cfu/mL. 21 -23 Based on the inoculum -AUC/MIC relationship found in the present study, a tAUC/MIC of 70 and 50 is required for 10 and 1 cfu/mL, respectively, which can be achieved for isolates with MICs of ≤0.06 mg/L for the standard dose and ≤0.125 mg/L for the higher dose of 100 mg for both inocula. The best outcome for low bacterial burden (≤1 cfu/mL) bloodstream infections treated with tigecycline monotherapy may be observed for isolates with MICs of 0.125 mg/L with the standard dose of 50 mg (40% PTA) and 0.25 mg/L with the higher dose of 100 mg (.73% PTA). Given that ,65% of isolates have MICs ≤0.25 mg/L, a more efficient approach for treating bloodstream infections is a combination therapy of tigecycline with other antibiotics that would simultaneously reduce the bacterial burden and the MIC of tigecycline in synergistic combinations, reaching the PD target even for isolates with higher MICs of tigecycline alone. 
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Bacterial load and pharmacodynamics of tigecycline JAC Interestingly, for patients with community-acquired pneumonia the fAUC 24 /MIC ratio associated with faster time to fever resolution was .12.8, which is very close to the fAUC 0 -24 /MIC ratio of 18 found in the present study for low inocula. 17 Lung biopsy studies showed that only 56% of patients with histological ventilator-associated pneumonia had .10 3 cfu/g even without antibiotic treatment. 26 Post-mortem biopsy studies in patients with pneumonia showed that although the cfu in bronchoalveolar lavage (BAL) ranged from 10 3 to 10 7 (mean 10 4 cfu/mL), the bacterial loads in lung biopsy samples did not exceed 10 5 cfu/g (mean between 10 2 and 10 3 cfu/g). 27 Given that bacteria are not uniformly distributed in lung parenchyma, but rather are concentrated in specific foci surrounded by normal parenchyma (http://www.pathologyatlas.ro/bronchopneumonia-lobularpneumonia.php), depending on the number of foci per g of lung tissue the bacterial load in each locus may be lower than the reported cfu/g values even for patients with 10 5 cfu/g (i.e. 10 3 cfu/g in each focus for 100 foci/g). Thus, the bacterial load in the lung parenchyma, which is the site of infection for patients with pneumonia, is low, which may explain the correlation of the in vitro PK/PD target for lower inocula with the clinical PK/PD target. The fact that ,65% of isolates have MICs ≤0.25 mg/L and some patients have high bacterial burden in lungs may explain the decreased performance of tigecycline therapy in ventilator-associated pneumonia (VAP) patients (http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ ucm370626.htm). The efficacy of tigecycline against lower inocula could also explain the increased survival in patients with infections treated with combination therapy where the second drug may decrease the bacterial load, enhancing the efficacy of tigecycline. 28 In the latter study, the microbiological eradication and clinical cure was two times higher with the dose of 100 mg compared with the standard dose of 50 mg (30% versus 57%), which is in accordance with higher PTA found for the 100 mg dose in the present study.
Previous clinical studies indicated an AUC 24 /MIC ratio of .17.9 for complicated skin and skin-structure infections (cSSSIs) 29 and .6.96 for complicated intra-abdominal infections (cIAIs), 30 which are both below the PK/PD targets (.150 tAUC 0 -24 /MIC) found in the present study although few infections were due to K. pneumoniae. However, similar to lung concentrations, skin tissue concentrations are (up to 8.8 times) higher than serum concentrations, 31 whereas intracellular concentrations of tigecycline in human polymorphonuclear neutrophils that are abundant in the peritoneum during cIAIs are 20 -30 times higher than extracellular concentrations. 32 These PK differences in serum and at the sites of infection may explain the discrepancies between in vitro and in vivo serum PK/PD targets for sSSSIs and cIAIs.
Currently the EUCAST susceptibility breakpoint of tigecycline for K. pneumoniae is 1 mg/L, which is much higher than the PK/PD breakpoints determined in the present study, even with the highest drug exposure and lowest inoculum. Based on the present study, for the standard 50 mg dose and for the higher 100 mg dose, susceptibility breakpoints of ≤0.06 and ≤0.125 mg/L, respectively, for bloodstream infections and ≤0.25 mg/L and ≤0.5 mg/L, respectively, for lung infections were determined considering that these infections have typical bacterial burdens of ≤10 1 and ≤10 3 cfu/mL, respectively, as shown above. Similar breakpoints have been previously found using Monte Carlo analysis and the clinical PK/PD target for complicated skin infections (S ≤ 0.25) and intra-abdominal infections (S≤ 0.5). 33 Our in vitro data are compatible with previous in vitro models showing inefficacy of tigecycline against K. pneumoniae isolates at 10 7 cfu/mL. 34 An inoculum effect on tigecycline bactericidal activity with 10 5 and 10 7 cfu/mL as the initial inoculum was found for E. coli, but not for Bacteroides fragilis or Enterococcus faecalis. 35 Previous animal experiments with a 24 h bacterial burden of 10 8 cfu/mL in the thigh found an fAUC/MIC of 5. 36 The same target was found in the present study when the maximal reduction of cfu observed within 6 h of incubation was used for the analysis with the 10 7 cfu/mL (data not shown). This indicates that the PK/PD target may be lower for a short-term effect, but higher for long-lasting effects. Unfortunately, most animal experiments last 24 h and therefore only the short-term effects are observed. Interestingly, in an animal model of K. pneumoniae pneumonia, a half-maximal activity ( 50% mortality and 3 -4 log 10 cfu/mL reduction in surviving mice) was found after 72 h at a serum AUC 0 -24 /MIC of 18.5-37. Considering the 10 times higher tigecycline concentrations in the lung, this target is close to the one determined in the present study for total drug, i.e. 590 for the high inoculum. 37 In conclusion, our in vitro study revealed an inoculum effect on tigecycline PD, with higher exposure indices required to produce the same effect with higher inocula. Considering that most cases of bacteraemia and pneumonia have low bacterial load (≤10 1 and ≤10 3 cfu/mL, respectively), PK/PD susceptibility breakpoints of ≤0.06 and ≤0.125 mg/L for bacteraemia and ≤0.25 and ≤0.5 mg/L for pneumonia for the standard dose of 50 mg and the higher dose of 100 mg, respectively, were determined. Given the MIC distribution of K. pneumoniae isolates, tigecycline monotherapy with either 50 or 100 mg would not be sufficient for most patients with bacteraemia, though only the higher dose of 100 mg could be sufficient for patients with pneumonia with low bacterial load.
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